Pacira Suit Seeks To Loosen FDA's Grip On Promotion
This article was originally published in Scrip
Executive Summary
Seeking to piggyback on what appears to be the FDA's reluctance to appeal a decision in a free-speech lawsuit brought by Amarin involving off-label promotion of its fish-oil pill Vascepa (icosapent ethyl), Pacira Pharmaceuticals has filed its own challenge against the agency – hoping to further loosen regulators' grip on what drug makers can discuss about their medicines with doctors and in promotional materials.